Dr Krishna Ella, Chairman and Managing Director of Bharat Biotech on Saturday (local time) said that the clinical phase III trials of the Covid-19 nasal vaccine have been completed and the company will submit its data with Drugs Controller General of India (DCGI) next month.

In an exclusive interview with ANI, Dr Ella said, "We just completed a clinical trial, a data analysis is going on. Next month, we will submit the data to the regulatory agency. If everything is okay, then we will get permission to launch and it will be the world's first clinically proven nasal Covid-19 vaccine". Krishna was in Paris as a speaker at Viva Technology 2022 where India was declared country of the year.